Publication details

Subependymální obrovskobuněčný astrocytom u pacientů s tuberózní sklerózou – farmakologická léčba mTOR inhibitory

Investor logo
Title in English Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex - Pharmacological Treatment using mTOR Inhibitors


Year of publication 2014
Type Article in Periodical
Magazine / Source Klinická onkologie
MU Faculty or unit

Faculty of Medicine

Field Oncology and hematology
Keywords subependymal giant cell astrocytoma; tuberous sclerosis complex; mTOR; everolimus
Description Tuberous sclerosis complex is a neurocutaneous syndrome that results from a germline muta-tion in TSC1 or TSC2 genes. The pathogenic activation of mTORCI leads to the development of subependymal giant cell astrocytomas in patients with tuberous sclerosis complex. Blocking of the dysregulated pathway with mTOR inhibitors has the potential to reduce the volume of this low-grade brain tumor. This article reviews the current knowledge on the pharmacolo¬gical treatment of subependymal giant cell astrocytomas. A long-term follow-up and early therapeutic intervention should lead to mortality and morbidity reduction and quality of life improvement in patients with tuberous sclerosis complex associated tumors.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info